Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 3/20 | 0.32 |
| ▸ | CA3 | P07451 | 2/20 | 0.32 |
| ▸ | CA5A | P35218 | 2/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16330639 | 0.95 | CA3 (0.39) | PKMKDM4ECA2CA3CA5A | |
| SCHEMBL145207 | 0.83 | — | — | |
| Hydrochloric Acid SCHEMBL17065917 | 0.81 | GSR (0.31) | — | |
| SCHEMBL15114186 | 0.80 | KDM4E (0.33) | PKMKDM4ECA2CA3CA5A | |
| SCHEMBL14064945 | 0.78 | CA5A (0.44) | PKMCA2CA3CA5ACA5B | |
| SCHEMBL15114210 | 0.77 | ALDH1A1 (0.31) | PKMKDM4E | |
| SCHEMBL10045231 | 0.76 | CA5A (0.43) | PKMCA2CA3CA5ACA5B | |
| SCHEMBL6811425 | 0.76 | PKM (0.31) | PKMCA2CA3CA5ACA5B | |
| SCHEMBL24619337 | 0.74 | CA12 (0.52) | PKMKDM4ECA2CA3CA5A | |
| SCHEMBL2608049 | 0.74 | TSHR (0.50) | CA2CA12CA7CA14CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2903436-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | UNIV PENNSYLVANIA (US) | 2019-07-17 | — | — | EP | disclosed |
| EP-2903436-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | UNIV PENNSYLVANIA (US) | 2019-07-17 | — | — | EP | disclosed |
| US-9994547-B2 | Heteroarylamide inhibitors of TBK1 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-12 | — | — | US | disclosed |
| US-20170313675-A1 | HETEROARYLAMIDE INHIBITORS OF TBK1 | TAKEDA CALIFORNIA, INC. | 2017-11-02 | — | — | US | disclosed |
| EP-3219207-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | The Trustees Of The University Of Pennsylvania (US) | 2017-09-20 | — | — | EP | disclosed |
| EP-3219207-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | The Trustees Of The University Of Pennsylvania (US) | 2017-09-20 | — | — | EP | disclosed |
| US-20170173016-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | NIH - DEITR | 2017-06-22 | — | — | US | disclosed |
| US-9649317-B2 | Heterocyclic compounds and their use for the treatment of neurodegenerative tauopathies | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2017-05-16 | — | — | US | disclosed |
| US-9598424-B2 | Heteroarylamide inhibitors of TBK1 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-21 | — | — | US | disclosed |
| US-20170015669-A1 | HETEROARYLAMIDE INHIBITORS OF TBK1 | TAKEDA CALIFORNIA, INC. | 2017-01-19 | — | — | US | disclosed |
| WO-2016057338-A1 | HETEROARYLAMIDE INHIBITORS OF TBK1 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-04-14 | — | — | WO | disclosed |
| WO-2015134171-A1 | HETEROARYLAMIDE INHIBITORS OF TBK1 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-11 | — | — | WO | disclosed |
| US-20150224105-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | NIH - DEITR | 2015-08-13 | — | — | US | disclosed |
| EP-2903436-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | The Trustees Of The University Of Pennsylvania (US) | 2015-08-12 | — | — | EP | disclosed |
| WO-2014047257-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-03-27 | — | — | WO | disclosed |
| WO-2014047257-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170173016-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | MAPT, PRNP, PSEN2 | PKM 203/4885KDM4E 2439/4885CA2 4459/4885 |
| US-20170015669-A1 | HETEROARYLAMIDE INHIBITORS OF TBK1 | TBK1, TBKBP1, TNKS1BP1 | PKM 1075/4885KDM4E 1465/4885CA2 4652/4885 |
| US-20150224105-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | MAPT, SYNJ1, PARK7 | PKM 368/4885KDM4E 3159/4885CA2 4714/4885 |
| US-20170313675-A1 | HETEROARYLAMIDE INHIBITORS OF TBK1 | TBK1, MAVS, IRF3 | PKM 2185/4885KDM4E 1783/4885CA2 4685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.